CN104585743A - Desertliving cistanche effervescent tablet and preparation technology thereof - Google Patents
Desertliving cistanche effervescent tablet and preparation technology thereof Download PDFInfo
- Publication number
- CN104585743A CN104585743A CN201310534891.4A CN201310534891A CN104585743A CN 104585743 A CN104585743 A CN 104585743A CN 201310534891 A CN201310534891 A CN 201310534891A CN 104585743 A CN104585743 A CN 104585743A
- Authority
- CN
- China
- Prior art keywords
- saline cistanche
- effervescent tablet
- preparation technology
- acid
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000005787 Cistanche Species 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 19
- 238000005516 engineering process Methods 0.000 title claims description 9
- 239000000284 extract Substances 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000011780 sodium chloride Substances 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 13
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 238000005469 granulation Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000011975 tartaric acid Substances 0.000 claims description 9
- 235000002906 tartaric acid Nutrition 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 238000007908 dry granulation Methods 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 238000007493 shaping process Methods 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 2
- 230000032683 aging Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 13
- 235000020985 whole grains Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 229960003511 macrogol Drugs 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 229910004298 SiO 2 Inorganic materials 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000011835 investigation Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- -1 benzyl carbinol glycoside Chemical class 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine preparation containing desertliving cistanche. The active components in desertliving cistanche extracts are used as raw materials, and raw material medicines of a certain proportion and carriers or auxiliary materials which are acceptable in pharmacy are made into an effervescent tablet. The medicine disclosed by the invention has the remarkable function of regulating immunity, and has the efficacies of resisting ageing, protecting the liver, enhancing memory, preventing Alzheimer's disease, promoting metabolism and the like.
Description
Technical field:
The present invention relates to a kind of health food strengthening body immunity, be specifically related to cistanche extracts and effervescent tablet thereof.
Background technology:
Saline cistanche is Chinese tradition parts of generic medicinal plants, " Chinese Pharmacopoeia " version in 2010 is recorded, and is the fleshy stem of the dry zone scale leaf of orobanchaceae plant cistanche Cistanche deserticola Y.C.Ma and Cistanche tubulosa Cistanche tubulosa (Schenk) wi ght.Main product in the Inner Mongol of China, Xinjiang, Gansu and Ningxia one is with, because its growth is in desert, and there is fabulous medical value, have the good reputation of " desert ginseng ".The fleshy stem of saline cistanche dry zone squama, has another name called ground essence, Jin Sun, desert cistanche, rues greatly.Begin to be loaded in " legendary god of farming's book on Chinese herbal medicine ", be classified as top grade, how on the books classic " Bencao Jingshu ", " book on Chinese herbal medicine remittance speech ", " Japan hanako materia medica " etc. be thereafter.Li Shizhen (1518-1593 A.D.) is said: " this thing is mended and not high, therefore have calm ".Saline cistanche taste is sweet, salty, warm in nature, tonifying kidney and strengthening yang, Tianjing Busuiye medicinal, enriching the blood to restore normal menstruation, and happy look such as to be prolonged life at the effect, under curing mainly impotence in male, female sterility, band, metrorrhagia, waist knee crymodynia, blood depletion constipation etc.Have the use history of more than 2,000 year in China, in successive dynasties reinforcement prescriptions of traditional Chinese medicine, occurrence rate holds pride of place, and in anti-senility class prescription, is only second to ginseng accounts for second.
Contained by saline cistanche, chemical composition comprises: polytype chemical compositions such as benzyl carbinol glycoside, iridoids, lignanoids, polysaccharide, alkaloid, trace element.Its main active benzyl carbinol glycoside of research report just has 20 multiple compounds, iridoids about to have tens kinds.
Pharmacological research shows that many-sided pharmacologically actives such as saline cistanche can regulate nervous system, anti-ageing and antioxidation, is improved memory, immunoregulation effect, anti-midbrain neural cells apoptosis, ischemic myocardial protection, improvement function, protects the liver, defecating feces excretion are widely used in clinical.Glycosides of Cistanche gavage can significantly improve the activity of the subacute aging mouse superoxide dismutase (SOD) caused by D-galactolipin, significantly reduces the lipid peroxide contents in brain, liver, shows stronger antioxidation and anti-aging effects; The delayed allergy irradiated by C0-60 can also be strengthened, increase thymus index, increase the activity of the reaction of T lymphocyte proliferation and raising interleukin-22 (IL-2).Oral administration obviously can increase the ability of macrophage and the weight of immune organ in mouse blood, and display cistanche glycosides compound has Promote immunity regulating action.
Saline cistanche sweet-salty, matter warm in nature moistens many liquid, returns kidney, large intestine channel.Having benefiting essence-blood, the effect relaxed bowel, is the product of strengthening both YIN and YANG.Motherland's medical science have accumulated rich experience with in saline cistanche treatment brain disorder disease, the kidney tonifying marrow facilitating such as record in " doctor new side " Holy Benevolent Prescriptions " General Records of Holy Universal Relief " supplement to the Herbal Thousand Golden Prescriptions that Cistanchis Bolus, saline cistanche rice starched pill, saline cistanche are loose, saline cistanche congee, saline cistanche soup, gold lock positive element are red, brain tonic and intelligence development side's treatment senile dementia, strengthens memory and has good curative effect.Modern Chinese herbal medicine " desert cistanche total saponin capsules " has obtained the accurate font size of traditional Chinese medicines, has kidney tonifying marrow facilitating, the merit of brain tonic and intelligence development, for the light moderate vascular dementia of marrow sea deficiency card.Another take saline cistanche as the old and feeble feature that the product of main component has " the red oral liquid that rues ", " Qi rue oral liquid ", " desert cistanche four times of balls ", the electuary etc. made with cistanche extracts significantly can improve human body, recover the suffer from a deficiency of the kidney energy of person in middle and old age and muscle power, all there is good delaying senility function.But have not yet to see the effervescent tablet made for raw material with the independent medicinal material of saline cistanche.
The present invention is raw material with saline cistanche, makes to utilize sodium acid carbonate and organic acid to meet water can to release the tablet that great amount of carbon dioxide forms effervesce shape, and this formulation has that disintegration is fast, onset rapid, and taking convenience, can improve bioavilability, improves clinical efficacy.
Summary of the invention:
The object of the invention is the value of exploiting and utilizing in order to improve saline cistanche medicinal material, select effervescent tablet preparation formulation, bioavilability is high, safe and effective, quality controllable, taking convenience.
For above-mentioned purpose, technical scheme provided by the invention is as follows:
The invention provides a kind of traditional Chinese medicinal material raw materials with immunity moderation function, described medicine is saline cistanche, and described saline cistanche by extracting, then by extract concentrate drying, makes effervescent tablet according to certain preparation prescription and preparation process further.
In the present invention, the extraction of saline cistanche medicinal material can in the following ways:
1, medicinal material water refluxing extraction
Get saline cistanche, 4 ~ 14 times amount refluxing extraction that adds water for the first time 2 times.
2, medicinal material alcohol extract
Get saline cistanche, with 10 ~ 95% ethanol 4 ~ 14 times amount refluxing extraction secondaries.
In the present invention, concentrated, the drying of the extract of saline cistanche medicinal material can in the following ways: by extract decompression and solvent recovery.Adopt vacuum drying, spraying dry or microwave drying mode dry.
Preparations shaping technique is in the following ways:
In preparation process, to extract extract powder for raw material, adopt single factor experiment method, using the compressibility of grain forming, mobility, sheet, hygroscopicity, dissolubility etc. as evaluation index, the acid source such as paratartaric acid, citric acid; To Macrogol 6000 whether inclusion alkali source; The fillers such as lactose, dextrin, sweet mellow wine, microcrystalline cellulose; SiO
2, dolomol, talcum powder, polyethylene glycol, glidant and the lubricant such as lauryl sodium sulfate, and the factors such as wheel speed, binder speed, charging rate, pressure of rolling of dry-pressing granulator are investigated.Study by experiment, determine that invention formulation prescription is:
Saline cistanche dry extract 10% ~ 30%; Acid source 20% ~ 35%; Filler 15% ~ 30%; Alkali source 15% ~ 35%; Glidant and lubricant 0.5% ~ 5%.
Specific experiment process is:
1, acid source
Select tartaric acid and citric acid as this product acid source, mix with dry extract and auxiliary material different proportion, dry granulation, the whole grain of 20-60 order, investigate preparation effect with dissolution rate and hydroscopicity.
2, filler
Select lactose, dextrin, sweet mellow wine, microcrystalline cellulose as this product filler, mix with dry extract and auxiliary material different proportion, dry granulation, the whole grain of 20-60 order, with shaping rate, angle of repose, dissolution rate and hydroscopicity investigate preparation effect,
3, soda acid consumption
Adopt L
9(3
4) carry out orthogonal experiment, by testing the optimum amount of preferred effervescent tablet mesotartaric acid, sodium acid carbonate, evaluation index is the comprehensive grading determination sodium acid carbonate consumption that the disintegration time of effervescent tablet and room temperature place the disintegration time after 30 days.
4, glidant and lubricant
Select SiO
2, dolomol, talcum powder, polyethylene glycol, lauryl sodium sulfate is as this product glidant and lubricant.
5, the usage ratio of each supplementary material
According to single factor test and orthogonal test determination supplementary material usage ratio.
Soda acid consumption and auxiliary material proportion process of the test and result as follows:
5.1 acid sources are investigated
Select tartaric acid and citric acid as this product acid source, mix with dry extract and auxiliary material different proportion, dry granulation, the whole grain of 20-60 order, investigate preparation effect with dissolution rate and hydroscopicity, the results are shown in Table 1.
Table 1 acid source investigates result
As can be seen from the above results, two kinds of proportioning dissolution rates are suitable, but No. 1, hydroscopicity No. 2 >.
The investigation of 5.2 fillers
Select lactose, dextrin, sweet mellow wine, microcrystalline cellulose as this product filler, mix, dry granulation with dry extract and auxiliary material different proportion, the whole grain of 20-60 order, with shaping rate, angle of repose, dissolution rate and hydroscopicity investigate preparation effect, the results are shown in Table 2.
The investigation result of table 2 filler
As can be seen from the above results, No. 1, granulates ratio of briquetting No. 3 > No. 4 > No. 2 >; Angle of repose is substantially suitable; No. 4, dissolution rate No. 1 > No. 3 > No. 2 >; No. 2, hygroscopicity No. 3 > No. 4 > No. 1 >; No. 1, alkali grain forming rate No. 3 > No. 2 > No. 4 >; Angle of repose is substantially suitable; No. 4, dissolution rate No. 1 > No. 3 > No. 2 >; No. 4, hygroscopicity No. 3 > No. 2 > No. 1 >.
5.3 with orthogonal test determination soda acid consumption
Adopt L
9(3
4) carry out orthogonal experiment, by testing the optimum amount of preferred effervescent tablet mesotartaric acid, sodium acid carbonate and polyethylene glycol, evaluation index is the comprehensive grading that the disintegration time of effervescent tablet and room temperature place the disintegration time after 30 days.The results are shown in Table 3,4.
Effervesce time (s) × 0.5 after comprehensive grading (s)=effervesce time (s) × 0.5+30 days
Table 3 empirical factor water-glass
Table 4 effervescent tablet moulding process L
9(3
4) orthogonal experiments
Table 5 the results of analysis of variance
| Soruces of variation | Sum of squares of deviations | The free degree | F value | P value |
| A | 1286.222 | 2 | 1.753 | |
| B | 49.556 | 2 | 0.068 | |
| C | 122.889 | 2 | 0.168 | |
| Error | 733.56 | 2 |
Be worth by intuitive analysis K, best moulding process is A
28
2c
2, i.e. tartaric acid consumption 685g, sodium acid carbonate consumption 771g Macrogol 6000 consumption 150g.
The investigation of 5.4 Macrogol 6000 inclusion sodium acid carbonates and not inclusion sodium acid carbonate
Mix with sodium acid carbonate after comparing No. 1 Macrogol 6000 melting, after cooling, pulverize; No. 2 sodium acid carbonates and Macrogol 6000 add respectively, two kinds of alkali sources and dry extract and other auxiliary materials and mixing, dry granulation,
The whole grain of 20-60 order, investigates preparation effect with hydroscopicity, the results are shown in Table 6.
The investigation table of table 6 Macrogol 6000 inclusion sodium acid carbonate and not inclusion sodium acid carbonate
As can be seen from the above results, No. 1, hygroscopicity No. 2 >, and No. 2 moisture absorption post-foamings are serious, therefore select No. 1 i.e. Macrogol 6000 inclusion sodium acid carbonate.
The selection of 5.5 glidants and lubricant
Select SiO
2, dolomol, talcum powder, polyethylene glycol, lauryl sodium sulfate as this product glidant and lubricant, test the preparation effect of No. 2 particles and auxiliary material different proportion, the results are shown in Table 7.
The investigation result of table 7 glidant and lubricant
As can be seen from the above results, No. 1 is selected namely to add SiO
2effect is best.
Detailed description of the invention:
Below in conjunction with specific embodiment, the present invention will be further described, and following each embodiment is not only limitation of the present invention for illustration of the present invention.
Embodiment 1:
(1) take the appropriate 1000g of saline cistanche, be broken into fritter, add water refluxing extraction twice, and the water extraction that first time adds 8000ml gets 2 hours, lets cool, and filters; Second time adds 6000ml water, extracts 1 hour, lets cool, and filters; Twice filtrate merges, and amounts to 12500ml, and concentrated, reduced pressure concentration relative density is 1.05 (60 DEG C) concentrate, and spraying dry, obtains medicinal powder 360g, for subsequent use;
(2) prescription supplementary material ratio is implemented in following ratio
(3) get 113g Macrogol 6000, after heating and melting, add the sodium acid carbonate of 487g, stir, let cool after solidifying, be ground into fine powder, cross 80 mesh sieves and 180g dried cream powder and 200g lactose and mix, 90% alcohol granulation, with the whole grain of 24 mesh sieve.
Got 80 order tartaric acid 460g, mixed with 180g dried cream powder and 200g lactose, citric acid 20g, 90% alcohol granulation, with the whole grain of 24 mesh sieve.
(4) by above-mentioned soda acid particle mixing, the SiO of 20g is added
2, mixing, compressing tablet, the heavy 0.5g of sheet, produces 3900 altogether.
Embodiment 2:
(1) take saline cistanche 1000g, be broken into fritter, add 70% alcohol reflux and extract twice, first time adds 70% ethanol 8000ml and extracts 2 hours, lets cool, and filters; Second time adds 70% ethanol 6000ml, extracts 1 hour, lets cool, and filters; Twice filtrate merges, and amount to 12300ml, be evaporated to relative density 1.30 (60 DEG C), microwave drying gets dry extract, and pulverizes, and crosses 80 mesh sieves, obtains medicinal powder 380g, for subsequent use;
(2) prescription supplementary material ratio is implemented in following ratio
(3) after getting 130g PVOH 6000 heating and melting, add sodium acid carbonate 650g, stir, let cool after solidifying, be ground into fine powder, 80 mesh sieves and 190g extract powder, 230g lactose, 58g Aspartame mix excessively, and 90% alcohol granulation, with the whole grain of 24 mesh sieve.
Got 80 order tartaric acid 575g, mixed with 190g extract powder, 230g lactose, 23g citric acid, 90% alcohol granulation, with the whole grain of 24 mesh sieve.
By above-mentioned soda acid particle mixing, add SiO
2, mixing, compressing tablet 0.5g, amounts to obtained 3940.
Embodiment 3:
(1) extract
Take the appropriate 1000g of saline cistanche, be broken into fritter, add 50% alcohol reflux and extract twice, first time adds 8000ml50% alcohol extract 2 hours, lets cool, and filters; Second time adds 50% ethanol of 6000ml, extracts 1 hour, lets cool, and filters; Twice filtrate merging amounts to 12000ml, concentrated, is evaporated to 1.30, microwave drying, gets dry extract, and pulverizes, and crosses 80 mesh sieves, obtains medicinal powder 370g, for subsequent use;
(2) prescription supplementary material ratio is implemented in following ratio
(3) after getting 91g Macrogol 6000 heating and melting, add 544g sodium acid carbonate, stir, let cool after solidifying, be ground into fine powder, cross 80 mesh sieves and 185g extract powder and 144g lactose and mix, 90% alcohol granulation, with the whole grain of 24 mesh sieve.
Got 80 mesh sieve tartaric acid 368g, mixed with 185g extract powder and 144g lactose, 90% alcohol granulation, with the whole grain of 24 mesh sieve.
By above-mentioned soda acid particle mixing, add the SiO of 32g
2, mixing, compressing tablet, the heavy 0.5g of sheet, produces 3910 altogether.
Embodiment 4:
Saline cistanche dry extract 12.5%; Acid source 25%; Filler 20%; Alkali source 28%; Glidant and lubricant 2%.
Acid source is tartaric acid or citric acid; Filler is lactose, dextrin, sweet mellow wine or microcrystalline cellulose; Alkali source is sodium acid carbonate; Glidant and lubricant are SiO
2, dolomol, talcum powder, polyethylene glycol or lauryl sodium sulfate.
Get saline cistanche appropriate, be broken into fritter, add 8 times amount 60-70% ethanol (or water) refluxing extraction twice, each 2 hours, filter, merging filtrate, reclaim ethanol, be condensed into thick paste, be dried to powder.After taking Macrogol 6000 heating and melting according to prescription ratio, add sodium acid carbonate, stir, let cool after solidifying, be ground into fine powder, cross 80 mesh sieves and 1/2 above-mentioned extract powder and lactose, Aspartame mixing mixing, 90% alcohol granulation, with the whole grain of 24 mesh sieve.
Got 80 order tartaric acid, with residue 1/2 extract powder and lactose, citric acid mixes, and 90% alcohol granulation, with the whole grain of 24 mesh sieve.
By above-mentioned soda acid particle mixing, add SiO
2, mixing, compressing tablet, both.Sheet weight: 0.5g.
Claims (6)
1. saline cistanche effervescent tablet and a preparation technology thereof, is characterized in that, comprises the following steps:
Step 1: the extraction of medicinal material
Get saline cistanche, 4 ~ 14 times amount refluxing extraction 2 times that adds water or by 10 ~ 95% ethanol 4 ~ 14 times amount refluxing extraction 2 times;
Step 2: extract is concentrated, dry
Step 3: preparations shaping
By saline cistanche dry extract 10% ~ 30%; Acid source 20% ~ 35%; Filler 15% ~ 30%; Alkali source 15% ~ 35%; Glidant and lubricant 0.5% ~ 5%; After mixing, dry granulation, compressing tablet, is prepared into saline cistanche effervescent tablet.
2. a kind of saline cistanche effervescent tablet according to claim 1 and preparation technology thereof, is characterized in that saline cistanche dry extract 12.5% in step 3; Acid source 25%; Filler 20%; Alkali source 28%; Glidant and lubricant 2%.
3. a kind of saline cistanche effervescent tablet according to claim 1 and preparation technology thereof, is characterized in that in step 1, concentration of alcohol is preferably 40 ~ 80%.
4. a kind of saline cistanche effervescent tablet according to claim 3 and preparation technology thereof, is characterized in that concentration of alcohol optimum is 70%.
5. a kind of saline cistanche effervescent tablet according to claim 1 and preparation technology thereof, is characterized in that in step 2, extract condensing mode is reduced pressure concentration; Drying mode is vacuum drying, spraying dry, belt drying, microwave drying and the granulation of fluid bed one step.
6. a kind of saline cistanche effervescent tablet according to claim 1 and preparation technology thereof, is characterized in that in step 3, and acid source is tartaric acid or citric acid; Filler is lactose, dextrin, sweet mellow wine or microcrystalline cellulose; Alkali source is sodium acid carbonate; Glidant and lubricant are superfine silica gel powder, dolomol, talcum powder, polyethylene glycol or lauryl sodium sulfate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310534891.4A CN104585743B (en) | 2013-11-04 | 2013-11-04 | A kind of Herba Cistanches effervescent tablet and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310534891.4A CN104585743B (en) | 2013-11-04 | 2013-11-04 | A kind of Herba Cistanches effervescent tablet and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104585743A true CN104585743A (en) | 2015-05-06 |
| CN104585743B CN104585743B (en) | 2018-11-13 |
Family
ID=53112078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310534891.4A Active CN104585743B (en) | 2013-11-04 | 2013-11-04 | A kind of Herba Cistanches effervescent tablet and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104585743B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105267175A (en) * | 2015-11-09 | 2016-01-27 | 广州丹奇日用化工厂有限公司 | Effervescent tablet and application thereof |
| CN106473038A (en) * | 2016-09-18 | 2017-03-08 | 天津北洋百川生物技术有限公司 | A kind of Herba Cistanches health-care tablet and preparation method thereof |
| CN107549571A (en) * | 2017-09-06 | 2018-01-09 | 张可池 | A kind of saline cistanche coix seed effervescent tablet and preparation method thereof |
| CN108652004A (en) * | 2018-03-29 | 2018-10-16 | 李昀芊 | A kind of Desert Herba Cistanches electuary of high-content and preparation method thereof |
| CN110495546A (en) * | 2019-03-12 | 2019-11-26 | 温通平 | One kind preparing solid beverage method based on Herba Cistanches |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766694A (en) * | 2008-12-26 | 2010-07-07 | 北京琥珀光华医药科技开发有限公司 | Process for extracting total glucosides from desertliving cistanche and preparation thereof |
-
2013
- 2013-11-04 CN CN201310534891.4A patent/CN104585743B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766694A (en) * | 2008-12-26 | 2010-07-07 | 北京琥珀光华医药科技开发有限公司 | Process for extracting total glucosides from desertliving cistanche and preparation thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105267175A (en) * | 2015-11-09 | 2016-01-27 | 广州丹奇日用化工厂有限公司 | Effervescent tablet and application thereof |
| CN106473038A (en) * | 2016-09-18 | 2017-03-08 | 天津北洋百川生物技术有限公司 | A kind of Herba Cistanches health-care tablet and preparation method thereof |
| CN107549571A (en) * | 2017-09-06 | 2018-01-09 | 张可池 | A kind of saline cistanche coix seed effervescent tablet and preparation method thereof |
| CN108652004A (en) * | 2018-03-29 | 2018-10-16 | 李昀芊 | A kind of Desert Herba Cistanches electuary of high-content and preparation method thereof |
| CN108652004B (en) * | 2018-03-29 | 2022-08-05 | 李昀芊 | Desert cistanche granule |
| CN110495546A (en) * | 2019-03-12 | 2019-11-26 | 温通平 | One kind preparing solid beverage method based on Herba Cistanches |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104585743B (en) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102895432A (en) | Prescription and preparation method of rejoicing powder having new dosage form | |
| CN103007052A (en) | Compound dendrobium extract composition capable of delaying senility | |
| CN104585743A (en) | Desertliving cistanche effervescent tablet and preparation technology thereof | |
| CN100542584C (en) | Compound hippophae rhamnoides lozenge and preparation method thereof | |
| CN103463307A (en) | Lucid ganoderma-corydalis saxicola compound chewable tablets and preparation method thereof | |
| CN105031301A (en) | Anti-tumor traditional Chinese medicine composition and preparation method thereof | |
| CN101011562B (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| CN1471845A (en) | Healthy food with glossy and rhizoma as main material and preparing method thereof | |
| CN103223104A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method | |
| CN104173585A (en) | Adaptogen preparation containing rhodiola rosea and preparation method thereof | |
| CN102657730A (en) | Rhodiola rosea buccal preparations for resisting altitude reaction | |
| CN101411779B (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
| CN102631482B (en) | Chinese medicinal composition for preventing and treating diabetes and complications | |
| CN109010514A (en) | Composition, health care product and the preparation method of altitude sickness prevention | |
| CN104922295A (en) | Blood-nourishing and blood-enriching traditional Chinese medicine composition | |
| CN101371875B (en) | Method for extracting and preparing total saponin of compound abnormal savda mature agent | |
| CN103446445A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN104095994B (en) | It is a kind of for Chinese medicine composition of functions of removing chloasma and preparation method thereof | |
| CN102614372A (en) | Chinese medicinal composition for resisting fatigue, and preparation method and application thereof | |
| CN101259156A (en) | Arenaria kansuensis solid state formulation and preparation thereof | |
| CN105169187B (en) | A kind of composition and its application, preparation method and drug, food containing the composition | |
| CN102614235A (en) | Acanthopanax root tea paste and preparation method thereof | |
| CN103816307B (en) | Nerve growth restorative bolus and preparation method thereof | |
| CN101214325A (en) | Method for preparing compound 'chenxiangwei'medicine and new use thereof | |
| CN105596663A (en) | Weight-losing drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170203 Address after: 010080 the Inner Mongolia Autonomous Region Saihan District of Hohhot City Shandan street Inner Mongolia science and technology building, room 1117 Applicant after: Inner Mongolia Rui Chen Biological Technology Co. Ltd. Address before: 010080 the Inner Mongolia Autonomous Region Saihan District of Hohhot City Shandan street Inner Mongolia science and technology building, room 706 Applicant before: Huhehaote City leads to auspicious science and technology limited Company |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |